Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Mallinckrodt
UBS
Fuji
US Department of Justice
Boehringer Ingelheim
Julphar
Harvard Business School
Moodys

Generated: May 28, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,686,411

« Back to Dashboard

Which drugs does patent 5,686,411 protect, and when does it expire?

Patent 5,686,411 protects SYMLIN and is included in one NDA.

This patent has thirty-one patent family members in sixteen countries.
Summary for Patent: 5,686,411
Title: Amylin agonist peptides and uses therefor
Abstract:Agonist analogues of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.
Inventor(s): Gaeta; Laura S. L. (Foster City, CA), Jones; Howard (Poway, CA), Albrecht; Elisabeth (San Diego, CA)
Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA)
Application Number:08/447,849
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 5,686,411

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-002 Sep 25, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN ➤ Sign Up
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-003 Sep 25, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN ➤ Sign Up
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-001 Mar 16, 2005 DISCN No No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,686,411

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,610,824 Amylin agonist peptides and uses therefor ➤ Sign Up
5,424,394 Synthetic preparation of amylin and amylin analogues ➤ Sign Up
7,271,238 Amylin agonist peptides and uses therefor ➤ Sign Up
5,998,367 Pramlintide pro H-amylin salts and compositions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Baxter
Boehringer Ingelheim
McKinsey
Dow
Citi
Argus Health
Moodys
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.